Hanmi Pharm’s new oral anticancer drug ‘Oraxol starts global Phase III clinical trial

They will actively start the global Phase III clinical trial of Oraxol, an oral anticancer drug developed by Hanmi Pharm.

A Hanmi Pharm’s partner, Athenex(Nasdaq: ATNX) announced that the company completed the Phase III patient registration for ‘Oraxol,’ the Hanmi Pharm’s new anticancer drug which applied the platform technology Orascovery, in a press release.

Oraxol, a new anticancer oral dr...